Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ben Adeyi, Beatriz Caballero, Paul Hodgkins, Richard Civil, David R. Coghill

    Research output: Contribution to journalArticle

    9 Citations (Scopus)
    64 Downloads (Pure)

    Abstract

    A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.
    Original languageEnglish
    Pages (from-to)1059-1069
    Number of pages11
    JournalCNS Drugs
    Volume28
    Issue number11
    DOIs
    Publication statusPublished - Nov 2014

    Fingerprint

    Methylphenidate
    Attention Deficit Disorder with Hyperactivity
    Outcome Assessment (Health Care)
    Safety
    Therapeutics
    Lisdexamfetamine Dimesylate
    Atomoxetine Hydrochloride

    Cite this

    Dittmann, Ralf W. ; Cardo, Esther ; Nagy, Peter ; Anderson, Colleen S. ; Adeyi, Ben ; Caballero, Beatriz ; Hodgkins, Paul ; Civil, Richard ; Coghill, David R. / Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. In: CNS Drugs. 2014 ; Vol. 28, No. 11. pp. 1059-1069.
    @article{7b36c536e57f4d64a96691c44d27f78f,
    title = "Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder",
    abstract = "A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.",
    author = "Dittmann, {Ralf W.} and Esther Cardo and Peter Nagy and Anderson, {Colleen S.} and Ben Adeyi and Beatriz Caballero and Paul Hodgkins and Richard Civil and Coghill, {David R.}",
    year = "2014",
    month = "11",
    doi = "10.1007/s40263-014-0188-9",
    language = "English",
    volume = "28",
    pages = "1059--1069",
    journal = "CNS Drugs",
    issn = "1172-7047",
    publisher = "Springer Verlag",
    number = "11",

    }

    Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. / Dittmann, Ralf W. (Lead / Corresponding author); Cardo, Esther; Nagy, Peter; Anderson, Colleen S.; Adeyi, Ben; Caballero, Beatriz; Hodgkins, Paul; Civil, Richard; Coghill, David R.

    In: CNS Drugs, Vol. 28, No. 11, 11.2014, p. 1059-1069.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

    AU - Dittmann, Ralf W.

    AU - Cardo, Esther

    AU - Nagy, Peter

    AU - Anderson, Colleen S.

    AU - Adeyi, Ben

    AU - Caballero, Beatriz

    AU - Hodgkins, Paul

    AU - Civil, Richard

    AU - Coghill, David R.

    PY - 2014/11

    Y1 - 2014/11

    N2 - A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.

    AB - A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.

    U2 - 10.1007/s40263-014-0188-9

    DO - 10.1007/s40263-014-0188-9

    M3 - Article

    VL - 28

    SP - 1059

    EP - 1069

    JO - CNS Drugs

    JF - CNS Drugs

    SN - 1172-7047

    IS - 11

    ER -